Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Abstract: A process for catalytic hydrogenation of aromatic amines can be performed. The aromatic amines can be methylenedianiline and/or tolylenediamine. The ring-hydrogenated equivalents can be obtained by contacting an input product, which have the aromatic amines and impurities, such as, alcohols, glycols, polyols, organic acids and/or water, with hydrogen in the presence of a catalyst. The catalyst can be platinum, palladium, rhodium, ruthenium, nickel, cobalt and/or iron. The catalyst is applied to a support, wherein the input product that has aromatic amines result from a PU decomposition process and contains impurities from this decomposition process.

Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.